Sotrovimab retains activity against SARS-CoV-2 Omicron variant BQ.1.1 in a non-human primate model
C. Herate, R. Marlin, F. Touret, N. D. Bosquet, F. Donati, F. Relouzat, L. Junges, M. Galhaut, O. Dehan, Q. Sconosciutti, A. Nougairede, X. de Lamballerie, S. van der Werf, R. Le Grand
This study shows Sotrovimab remains effective against SARS-CoV-2 BQ.1.1 in a non-human primate model, as measured by reduced viral replication.
bioRxiv · Feb 15, 2023Pathology